Overview

Saudi Arabias pharma and biotech sector is expected to grow rapidly in the coming years due to population growth and increased demand for chronic disease treatment. With a predicted CAGR of 7.3% over the next 6 years, the sector offers attractive first mover advantages given the relatively low penetration of leading global pharmaceuticals manufacturers with local production facilities.

Overview

healthcare and life sciences hub where companies will locate their research, development, production and headquarter activities across the entire biomedical value chain. On the Research and Development side, we aim to elevate and invigorate scientific research activities from early drug discovery to clinical trials. On the manufacturing front, we aspire to boost local capabilities and position Saudi Arabia as a major regional export-driven hub. On the clinical care side, we aim to enable the delivery of high quality, innovative, value-based healthcare solutions and services. To achieve these objectives and to build end-to-end capabilities in the sector, we are investing in the development of a robust infrastructure for the biomedical ecosystem. This includes multi-sectorial partnerships, favorable policies and regulations, competitive incentives, talent & expertise, and sustained financing. Our key priority areas and ambitions for the biomedical science and pharmaceutical industry include areas like clinical research, personalized medicine, value-based healthcare, AI in drug discovery, and the localization of biologics, vaccines, and cell & gene therapy.